Deferred Tax Assets, Valuation Allowance of Trevi Therapeutics, Inc. from 31 Dec 2018 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Trevi Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2018 to 31 Dec 2024.
  • Trevi Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $82,449,000, a 19% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Trevi Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $82,449,000 +$12,947,000 +19% 31 Dec 2024 10-K 18 Mar 2025 2024 FY
Q4 2023 $69,502,000 +$8,430,000 +14% 31 Dec 2023 10-K 18 Mar 2025 2024 FY
Q4 2022 $61,072,000 +$8,376,000 +16% 31 Dec 2022 10-K 20 Mar 2024 2023 FY
Q4 2021 $52,696,000 +$9,867,000 +23% 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q4 2020 $42,829,000 +$9,534,000 +29% 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q4 2019 $33,295,000 +$7,360,000 +28% 31 Dec 2019 10-K 25 Mar 2021 2020 FY
Q4 2018 $25,935,000 31 Dec 2018 10-K 16 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.